The value of contraception to prevent perinatal HIV transmission
- PMID: 16505747
- DOI: 10.1097/01.olq.0000194602.01058.e1
The value of contraception to prevent perinatal HIV transmission
Abstract
Objective: The objective of this study was to highlight the value of preventing unintended pregnancies among HIV-infected women as a strategy to prevent perinatal HIV transmission.
Goal: The goal of this study was to assess the cost-effectiveness of family planning programs to avert HIV-positive births with the current programmatic emphasis: prenatal care services that provide and promote nevirapine for prevention of mother-to-child transmission of HIV.
Study design: Cost-effectiveness analyses were conducted from the health system perspective during 1 year with a hypothetical sub-Saharan African population. Expected program costs were combined with number of HIV-positive births averted for each strategy.
Results: At the same level of expenditure, the contraceptive strategy averts 28.6% more HIV-positive births than nevirapine for prevention of mother-to-child transmission of HIV.
Conclusions: Increasing contraceptive use among nonusers of contraception who do not want to get pregnant is cost-effective and is an equally important strategy to prevent perinatal transmission as prenatal care programs that provide and promote nevirapine to HIV-infected mothers.
Similar articles
-
Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.Med Decis Making. 2004 Jan-Feb;24(1):30-9. doi: 10.1177/0272989X03261570. Med Decis Making. 2004. PMID: 15005952
-
Contraception to prevent HIV-positive births: current contribution and potential cost savings in PEPFAR countries.Sex Transm Infect. 2008 Oct;84 Suppl 2:ii49-53. doi: 10.1136/sti.2008.030049. Sex Transm Infect. 2008. PMID: 18799493
-
Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.Lancet. 1999 Sep 4;354(9181):803-9. doi: 10.1016/S0140-6736(99)80009-9. Lancet. 1999. PMID: 10485721
-
Mothers, midwives, and HIV/AIDS in Sub-Saharan Africa.J Midwifery Womens Health. 2005 Jul-Aug;50(4):275-82. doi: 10.1016/j.jmwh.2005.03.021. J Midwifery Womens Health. 2005. PMID: 15973262 Review.
-
Prevention of mother-to-child transmission of HIV--successes, controversies and critical questions.AIDS Rev. 2004 Jul-Sep;6(3):131-43. AIDS Rev. 2004. PMID: 15595430 Review.
Cited by
-
Differences in the Nonuse of any Contraception and Use of Specific Contraceptive Methods in HIV Positive and HIV Negative Rwandan Women.AIDS Res Treat. 2012;2012:367604. doi: 10.1155/2012/367604. Epub 2012 Dec 17. AIDS Res Treat. 2012. PMID: 23304468 Free PMC article.
-
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.J Antimicrob Chemother. 2022 Oct 28;77(11):3144-3152. doi: 10.1093/jac/dkac296. J Antimicrob Chemother. 2022. PMID: 36059130 Free PMC article.
-
A systematic review of contraceptive continuation among women living with HIV.Contraception. 2018 Jul;98(1):8-24. doi: 10.1016/j.contraception.2018.02.002. Epub 2018 Feb 9. Contraception. 2018. PMID: 29432719 Free PMC article.
-
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic.J Clin Invest. 2008 Apr;118(4):1244-54. doi: 10.1172/JCI34706. J Clin Invest. 2008. PMID: 18382737 Free PMC article. Review.
-
Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe.J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):157-64. doi: 10.1097/QAI.0b013e318214ba4a. J Acquir Immune Defic Syndr. 2011. PMID: 21358412 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical